Loading clinical trials...
Loading clinical trials...
Tagraxofusp (SL-401) Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients Post-Autologous or Post-Allogeneic Hematopoietic Cell Transplantation
Conditions
Interventions
Tagraxofusp-erzs
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
March 27, 2020
Primary Completion Date
July 11, 2023
Completion Date
July 11, 2023
Last Updated
July 31, 2024
NCT05362773
NCT06690827
NCT06006403
NCT02159495
NCT04013685
NCT07007052
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions